STK11 mutant NSCLC with KRAS co-mutations are associated with increased IL-6, IL-1β, and CXCL7 levels along with neutrophil infiltration, yet decreased T-cell infiltration and function, decreased PD-L1 expression, and decreased stimulator of interferon genes (STING) pathway activation. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.